{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:25:11Z","timestamp":1794925511700,"version":"4.9.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to summarize the clinical characteristics and prognosis of patients with anti- acetylcholine receptor (AChR) positive myasthenia gravis (MG) with a combination of anti-LRP4 or Titin antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 188 patients with generalized MG before immunotherapy were retrospectively collected and then divided into three groups: single anti-AChR positive-MG (AChR-MG, 101 cases), anti-AChR combined with anti-low-density lipoprotein receptor-related protein four-positive MG (AChR+LRP4-MG, 29 cases), and anti-AChR combined with anti-Titin-positive MG (AChR+Titin-MG, 58 cases). Clinical manifestations, therapeutic responses to immunotherapy, and follow-up information were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 188 seropositive MG patients, 29 (15.4%) were positive for both AChR and LRP4 antibodies, and 58 (30.9%) were positive for both AChR and Titin antibodies. The mean disease onset ages in the three groups were 47.41 \u00b1 7.0, 49.81 \u00b1 9.2, and 48.11 \u00b1 6.5 years, respectively. AChR+LRP4-MG showed female predominance (27.6% were males and 72.4% were females), with mild overall clinical symptoms. The AChR+Titin-MG group showed shorter times for conversion to generalized MG (5.14 \u00b1 0.0 months) than the AChR-MG group (11.69 \u00b1 0.0 months) and the AChR+LRP4-MG group (13.08 \u00b1 0.5 months; <jats:italic>P<\/jats:italic> &amp;lt; 0.001 in both cases). Furthermore, AChR+Titin-MG group had increased bulbar dysfunction, higher incidences of thymoma (32.8 vs. 19.8% and 3.4%, <jats:italic>P<\/jats:italic>=0.035), more severe quantitative MG scores, as assessed by both QMG scores [15.5 (11.75\u201322.5) vs. 13 (8\u201319), <jats:italic>P<\/jats:italic> = 0.005; and 9 (6\u201314) <jats:italic>P<\/jats:italic> &amp;lt; 0.001], and MG-ADL scores [10 (8\u201313) vs. 8 (5\u201313), <jats:italic>P<\/jats:italic> = 0.018; and 6 (4\u20138), <jats:italic>P<\/jats:italic> &amp;lt; 0.001]. Treatment for AChR+Titin-MG was largely dependent on corticosteroids and immunosuppressive agents (56.7 vs. 19.2% and 16.7%, <jats:italic>p<\/jats:italic> = 0.028). The rates of achieving s(MMS) or better within 2 years following immunotherapy in the three groups were 51.5, 62.1, and 51.7%, respectively (<jats:italic>P<\/jats:italic> = 0.581).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clinical symptoms of anti-AChR positive MG combined with Titin antibody were more severe and progressed faster than those in the AChR + LRP4 and AChR groups. Regardless of antibody status, all patients responded well to immunotherapy and had relatively good prognoses.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.873599","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T06:23:02Z","timestamp":1652077382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuping","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"9","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia Gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol Scand Suppl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.37.8.1329","article-title":"Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis","volume":"37","author":"Yamamoto","year":"1987","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/nyas.13502","article-title":"Diagnostic utility of cortactin antibodies in myasthenia gravis","volume":"1412","author":"Illa","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"and O'Connor KC. Autoimmune pathology in myasthenia gravis disease subtypes Is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \u201cseronegative\u201d myasthenia gravis\u2013a new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1212\/WNL.59.1.92","article-title":"The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999","volume":"59","author":"Somnier","year":"2002","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: A multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve."},{"key":"B15","doi-asserted-by":"publisher","first-page":"516211","DOI":"10.3389\/fneur.2020.516211","article-title":"Regional features of MuSK antibody-positive myasthenia gravis in northeast China","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis-autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mus.25591","article-title":"Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis","volume":"56","author":"Li","year":"2017","journal-title":"Muscle Nerve."},{"key":"B20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jns.2014.09.013","article-title":"Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms","volume":"346","author":"Tsivgoulis","year":"2014","journal-title":"J Neurol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14737175.2017.1241144","article-title":"Myasthenia gravis: recent advances in immunopathology and therapy","volume":"17","author":"Lee","year":"2017","journal-title":"Expert Rev Neurother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"594152","DOI":"10.3389\/fneur.2020.594152","article-title":"Favorable effects of tacrolimus monotherapy on myasthenia gravis patients","volume":"11","author":"Fan","year":"2020","journal-title":"Front Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.873599\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T06:23:04Z","timestamp":1652077384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.873599\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":28,"alternative-id":["10.3389\/fneur.2022.873599"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.873599","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"873599"}}